Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With

Frexalimab (anti-CD40L) showed strong Phase 2 results in RMS with ~89% reduction in new Gd-enhancing T1 lesions vs placebo. Mechanism is well-validated for MS inflammation. ARR superiority vs teriflunomide (a modest-efficacy comparator) is a reasonable bar for a potent B/T-cell costimulation blocker. Phase 3 ARR trials in RMS with active comparators have solid historical success rates (~65-75%). Main risks: teriflunomide is active control (not placebo), long 156-week duration, and execution.

Phase 3, active-not-recruiting status lowers execution risk, while adjudicated ARR over a long period with ITT negative-binomial analysis is a robust endpoint. However, superiority versus active teriflunomide is a meaningful hurdle, and event-driven variable follow-up adds uncertainty.

Phase 3, event-driven relapsing-MS studies use adjudicated ARR through Week 156 against teriflunomide, a credible but modest-efficacy active comparator. Long follow-up and ITT negative-binomial analysis support endpoint sensitivity, but success depends on durable relapse suppression, retention, and execution across two independent studies.

Phase 3, event-driven design with a long treatment horizon and protocol-defined adjudicated ARR provide a robust efficacy test. Relapsing MS is a suitable population and active teriflunomide control raises evidentiary quality, but the comparator is demanding. Missing sample-size, effect-size, and prior-result details create meaningful statistical and disclosure risk.

Phase 3 event-driven design, adjudicated ARR primary endpoint via negative binomial in ITT with proper strata. Standard teriflunomide comparator, 18-55yo relapsing MS population, variable duration >=12mo. No prior data or risks detailed; long 2027 completion raises execution/disclosure uncertainty.

Frexalimab, an Fc-silent anti-CD40L mAb, demonstrated an 89% reduction in new Gd-enhancing T1 lesions vs placebo in Phase 2. In MS, strong MRI lesion suppression reliably predicts robust ARR reduction. Since the active comparator teriflunomide offers only moderate efficacy, frexalimab is highly likely to achieve superiority. Fc-silencing mitigates historical anti-CD40L thromboembolic risks.

Phase 2 frexalimab showed 89% reduction in Gd-enhancing lesions vs placebo but limited relapse data. Phase 3 uses ARR vs active comparator teriflunomide, a modest efficacy DMT. Superiority is plausible but not assured given long event-driven design and execution risk. Estimated 55% success.

Frexalimab Phase 2b showed strong MRI lesion reduction in RMS, and the active comparator teriflunomide is a moderate-efficacy DMT that multiple agents have beaten on ARR. Sanofi has strong operational execution. However, anti-CD40L is a novel mechanism for MS with uncertain translation from MRI to clinical relapse endpoints, and historical thromboembolic safety concerns with CD40L antibodies add risk. Net odds favor success but with meaningful residual uncertainty.

Frexalimab targets CD40L, a novel MOA in MS with strong Phase 2 efficacy signals. Sanofi's active-not-recruiting status suggests robust enrollment. Head-to-head vs teriflunomide is a standard comparator; given the strong mechanistic rationale and prior data, a positive ARR result is likely despite Phase 3 execution risks.

Phase‑3 MS trial comparing frexalimab to teriflunomide and placebo. ARR endpoint is hard, event‑driven, and historically modest effect sizes for novel antibodies. Limited recruitment data, active not recruiting, and no early read‑outs suggest ~35% chance of showing a statistically significant ARR reduction.

Frexalimab is a CD40L inhibitor with strong Phase 2 data in MS showing 89% reduction in new Gd+ lesions vs placebo. Phase 3 design is event-driven with ~40-month max follow-up, powered for ARR vs teriflunomide (active comparator). Sanofi has deep MS expertise. Active-not-recruiting status suggests enrollment complete, reducing execution risk. Primary endpoint is standard and well-defined. Main risks: longer duration increases dropout/noise, and anti-CD40L class has seen thrombotic safety signals historically (though not in Phase 2).

Frexalimab Phase 2 showed strong ARR reductions (~60-70%) vs placebo with engineered CD40L mAb addressing thrombotic risk. Active not recruiting signals good execution. However, Phase 3 uses active comparator teriflunomide (approved therapy), raising the bar vs placebo. MS Phase 3 trials with active comparators have mixed track record (evobrutinib, tolebrutinib disappointments). Event-driven design is sound. ~16 months to readout adds execution/disclosure risk. Net: positive but not high conviction given comparator hurdle.